CML in pregnancy and childhood

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 455-474

  Apperley, Jane ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

adolescents; children; fertility; pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BUSULFAN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; LOW MOLECULAR WEIGHT HEPARIN; NILOTINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGENITAL MALFORMATION; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MILK LEVEL; DRUG SAFETY; DRUG TREATMENT FAILURE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GONAD DEVELOPMENT; GRAFT VERSUS HOST REACTION; HEART FAILURE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LEUKAPHERESIS; LEUKEMIA REMISSION; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; NAUSEA; NONHUMAN; OVARIAN PRESERVATION; OVERALL SURVIVAL; PLEURA EFFUSION; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SOLID TUMOR; SPERM PRESERVATION; SPONTANEOUS ABORTION; TERATOGENICITY; UNPLANNED PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ADULT; AGE FACTORS; CHILD; FEMALE; FETAL DISEASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MATERNAL-FETAL EXCHANGE; PIPERAZINES; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71849109234     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.09.008     Document Type: Review

References (119)

1. Green D.M., Sklar C.A., Boice Jr. J.D., et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 27 14 (2009) 2374-2381
2. Salooja N., Szydlo R.M., Socie G., et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 358 9278 (2001) 271-276
3. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26 20 (2008) 3358-3363
4. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (2006) 2408-2417
5. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8 16 (1994) 1888-1896
6. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124 14 (1997) 2691-2700
7. Hoch R.V., and Soriano P. Roles of PDGF in animal development. Development 130 20 (2003) 4769-4784
8. Tybulewicz V.L., Crawford C.E., Jackson P.K., et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65 7 (1991) 1153-1163
9. Mauduit C., Hamamah S., and Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update 5 5 (1999) 535-545
10. Nurmio M., Toppari J., Zaman F., et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl 30 4 (2007) 366-376
11. Basciani S., De Luca G., Dolci S., et al. Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes. Endocrinology 149 12 (2008) 6226-6235
12. Nurmio M., Kallio J., Toppari J., et al. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol 25 4 (2008) 442-446
13. Seshadri T., Seymour J.F., and McArthur G.A. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 351 20 (2004) 2134-2135
14. Christopoulos C., Dimakopoulou V., and Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 358 10 (2008) 1079-1080
15. Hensley M.L., and Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 2 Suppl. 3 (2003) 21-25
16. Ault P., Kantarjian H., O'Brien S., et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24 7 (2006) 1204-1208
17. Ramasamy K., Hayden J., Lim Z., et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137 4 (2007) 374-375
18. Breccia M., Cannella L., Montefusco E., et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 32 3 (2008) 519-520
19. Cortes J., O'Brien S., Ault P., et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112 11 (2008) 1109
20. Meera V., Jijina F., Shrikande M., et al. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy. Leuk Res (2008)
21. Buyukbayrak E.E., Ergen B., Karsidag Y.K., et al. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet (2008)
22. Yilmaz M., Demirhan O., Kucukosmanoglu E., et al. Pregnancy in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma 48 12 (2007) 2454-2456
23. Koh L.P., and Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. Int J Hematol 84 5 (2006) 459-462
24. Ali R., Ozkalemkas F., Ozcelik T., et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 29 8 (2005) 971-973
25. Ali R., Ozkalemkas F., Ozkocaman V., et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 34 4 (2004) 215-217
26. Choudhary D.R., Mishra P., Kumar R., et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 17 1 (2006) 178-179
27. Prabhash K., Sastry P.S., Biswas G., et al. Pregnancy outcome of two patients treated with imatinib. Ann Oncol 16 12 (2005) 1983-1984
28. AlKindi S., Dennison D., and Pathare A. Imatinib in pregnancy. Eur J Haematol 74 6 (2005) 535-537
29. Heartin E., Walkinshaw S., and Clark R.E. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 45 6 (2004) 1307-1308
30. Garderet L., Santacruz R., Barbu V., et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 92 1 (2007) e9-10
31. Suppiah R., and Kalaycio M. Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester. Leuk Lymphoma 47 6 (2006) 1149-1150
32. Skoumalova I., Vondrakova J., Rohon P., et al. Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152 1 (2008) 121-123
33. Dolai T.K., Bhargava R., Mahapatra M., et al. Is imatinib safe during pregnancy?. Leuk Res 33 4 (2009) 572-573
34. Sora F., De Matteis S., Bajer J., et al. Persistence of molecular remission throughout pregnancy in CML after imatinib. Leuk Res 33 6 (2009) e6-e7
35. Klamova H., Markova M., Moravcova J., et al. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. Leuk Res (2009)
36. Pye S.M., Cortes J., Ault P., et al. The effects of imatinib on pregnancy outcome. Blood (2008)
37. Calzolari E., Bianchi F., Dolk H., et al. Omphalocele and gastroschisis in Europe: a survey of 3 million births 1980-1990. EUROCAT Working Group. Am J Med Genet 58 2 (1995) 187-194
38. Robertson S.C., Tynan J., and Donoghue D.J. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 16 8 (2000) 368
39. He K., Lago M.W., Iyer R.A., et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 36 12 (2008) 2564-2570
40. Russell M.A., Carpenter M.W., Akhtar M.S., et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27 4 (2007) 241-243
41. Ali R., Ozkalemkas F., Kimya Y., et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280 2 (2009) 169-175
42. Kronenberger R., Schleyer E., Bornhauser M., et al. Imatinib in breast milk. Ann Hematol (2009)
43. Doll D.C., Ringenberg Q.S., and Yarbro J.W. Antineoplastic agents and pregnancy. Semin Oncol 16 5 (1989) 337-346
44. Rahman M.E., Ishikawa H., Watanabe Y., et al. Carpal and tarsal bone development is highly sensitive to three antiproliferative teratogens in mice. Reprod Toxicol 10 6 (1996) 485-489
45. Delmer A., Rio B., Bauduer F., et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol 82 4 (1992) 783-784
46. Patel M., Dukes I.A., and Hull J.C. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. Am J Obstet Gynecol 165 3 (1991) 565-566
47. Tertian G., Tchernia G., Papiernik E., et al. Hydroxyurea and pregnancy. Am J Obstet Gynecol 166 6 Pt 1 (1992) 1868
48. Jackson N., Shukri A., and Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 85 1 (1993) 203-204
49. Sylvester R.K., Lobell M., Teresi M.E., et al. Excretion of hydroxyurea into milk. Cancer 60 9 (1987) 2177-2178
50. Caplan S.N., Coco F.V., and Berkman E.M. Management of chronic myelocytic leukemia in pregnancy by cell pheresis. Transfusion 18 1 (1978) 120-124
51. Broccia G., Casula P., and Andria M. Chronic myelocytic leukemia in pregnancy: report of a case treated with leukapheresis. Tumori 70 4 (1984) 371-374
52. Fitzgerald D., Rowe J.M., and Heal J. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol 22 2 (1986) 213-218
53. Bazarbashi M.S., Smith M.R., Karanes C., et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol 38 3 (1991) 235-237
54. Girling J.C., and de Swiet M. Thromboembolism in pregnancy: an overview. Curr Opin Obstet Gynecol 8 6 (1996) 458-463
55. Riyazi N., Leeda M., de Vries J.I., et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 80 1 (1998) 49-54
56. Ginsberg J.S., Greer I., and Hirsh J. Use of antithrombotic agents during pregnancy. Chest 119 1 Suppl. (2001) 122S-131S
57. Ginsberg J.S., and Bates S.M. Management of venous thromboembolism during pregnancy. J Thromb Haemost 1 7 (2003) 1435-1442
58. Maher J.E., Owen J., Hauth J., et al. The effect of low-dose aspirin on fetal urine output and amniotic fluid volume. Am J Obstet Gynecol 169 4 (1993) 885-888
59. Owen J., Maher J.E., Hauth J.C., et al. The effect of low-dose aspirin on umbilical artery Doppler measurements. Am J Obstet Gynecol 169 4 (1993) 907-911
60. Martinelli P., Martinelli V., Agangi A., et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol 191 6 (2004) 2016-2020
61. Milano V., Gabrielli S., Rizzo N., et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 5 2 (1996) 74-78
62. Pardini S., Dore F., Murineddu M., et al. Alpha 2b-interferon therapy and pregnancy-report of a case of essential thrombocythemia. Am J Hematol 43 1 (1993) 78-79
63. Petit J.J., Callis M., and Fernandez d.S. Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b. Am J Hematol 40 1 (1992) 80
64. Pons J.C., Lebon P., Frydman R., et al. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 10 1 (1995) 7-10
65. Goh H.G., Kim Y.J., Kim D.W., et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 50 6 (2009) 944-951
66. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 1 (2007) 58-60
67. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 42 Suppl. 2 (2008) S40-S46
68. Birch J.M., Alston R.D., Quinn M., et al. Incidence of malignant disease by morphological type, in young persons aged 12-24 years in England, 1979-1997. Eur J Cancer 39 18 (2003) 2622-2631
69. Horibe K., Tsukimoto I., and Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia 15 8 (2001) 1256-1261
70. Preston D.L., Kusumi S., Tomonaga M., et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. [published erratum appears in Radiat Res 1994 Jul;139(1):129]. Radiat Res 137 2 Suppl (1994) S68-S97
71. Millot F., Traore P., Guilhot J., et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116 1 (2005) 140-143
72. Aurer I., Butturini A., and Gale R.P. BCR-ABL rearrangements in children with Philadelphia chromosome- positive chronic myelogenous leukemia. Blood 78 9 (1991) 2407-2410
73. Fioretos T., Heim S., Garwicz S., et al. Molecular analysis of Philadelphia-positive childhood chronic myeloid leukemia. Leukemia 6 7 (1992) 723-725
74. Hasan S.K., Sazawal S., Kumar B., et al. Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genet Cytogenet 169 1 (2006) 76-77
75. Adler R., Viehmann S., Kuhlisch E., et al. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 82 2 (2009) 112-118
76. Mills K.I., Benn P., and Birnie G.D. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 78 5 (1991) 1155-1161
77. Inokuchi K., Inoue T., Tojo A., et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. [see comments]. Blood 78 12 (1991) 3125-3127
78. Bianchi C., Cairoli R., Marenco P., et al. Detection by polymerase chain reaction of BCR/ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation. Eur J Cancer 31A 2 (1995) 197-201
79. Shepherd P., Suffolk R., Halsey J., et al. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 89 3 (1995) 546-554
80. Perego R.A., Costantini M., Cornacchini G., et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 36 11 (2000) 1395-1401
81. Arana-Trejo R.M., Ruiz S.E., Ignacio-Ibarra G., et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 24 3 (2002) 145-150
82. Giona F., Moleti M.L., Del G.I., et al. Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period. Br J Haematol 130 6 (2005) 970-972
83. Richards S.M. Interferon-alpha: results from randomized trials. Baillieres Clin Haematol 10 2 (1997) 307-318
84. Dow L.W., Raimondi S.C., Culbert S.J., et al. Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer 68 8 (1991) 1678-1684
85. Millot F., Guilhot J., Nelken B., et al. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia. Pediatr Blood Cancer 47 5 (2006) 555-559
86. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99 6 (2002) 1971-1977
87. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 102 4 (2003) 1224-1231
88. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352 9134 (1998) 1087-1092
89. Creutzig U., Ritter J., Zimmermann M., et al. Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients. Klin Padiatr 208 4 (1996) 236-241
90. Millot F., Esperou H., Bordigoni P., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 32 10 (2003) 993-999
91. Horn B., Baxter-Lowe L.A., Englert L., et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 37 3 (2006) 263-269
92. Satwani P., Harrison L., Morris E., et al. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 11 6 (2005) 403-422
93. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106 9 (2005) 2969-2976
94. Kaeda J., O'shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 107 10 (2006) 4171-4176
95. Dazzi F., Szydlo R.M., Cross N.C., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96 8 (2000) 2712-2716
96. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17 9 (2003) 1707-1712
97. Levine J.E., Barrett A.J., Zhang M.J., et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 42 3 (2008) 201-205
98. Milojkovic D., Bua M., Apperley J.F., et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. Blood 112 11 (2008) 129
99. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104 9 (2004) 2655-2660
100. Berman E., Nicolaides M., Maki R.G., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354 19 (2006) 2006-2013
101. Dewar A.L., Farrugia A.N., Condina M.R., et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 107 11 (2006) 4334-4337
102. Fitter S., Dewar A.L., Kostakis P., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 111 5 (2008) 2538-2547
103. Aplenc R., Strauss L.C., Shusterman S., et al. Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: a report from the Children's Oncology Group Phase I consortium. Journal of Clinical Oncology 26 (2008) 20-25 [Ref Type: Abstract]
104. Zwaan C.M., Rizzari C., van der Velden V.H.J., et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase i study from the ITCC Consortium. Blood 112 11 (2008) 1113
105. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 15 (2003) 1423-1432
106. Sanders J.E., Guthrie K.A., Hoffmeister P.A., et al. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 105 3 (2005) 1348-1354
107. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98 13 (2001) 3569-3574
108. Baker K.S., Gurney J.G., Ness K.K., et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 104 6 (2004) 1898-1906
109. Ness K.K., Bhatia S., Baker K.S., et al. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch Pediatr Adolesc Med 159 8 (2005) 706-713
110. Gurney J.G., Ness K.K., Rosenthal J., et al. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer 106 6 (2006) 1402-1408
111. Perz J.B., Khorashad J.S., Marin D., et al. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 91 8 (2006) 1145-1146
112. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 109 4 (2007) 1782-1789
113. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91 4 (2006) 452-459
114. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112 8 (2008) 3500-3507
115. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 6 (2006) 1809-1820
116. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood (2008)
117. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 6 (2007) 2303-2309
118. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 10 (2007) 3540-3546
119. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112 3 (2008) 516-518